Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients

HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions

(2013) Nicola Fusco et al.   MODERN PATHOLOGY

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

(2012) V. S. Warneke et al.   ANNALS OF ONCOLOGY

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

(2012) I Witzel et al.   BRITISH JOURNAL OF CANCER

Current status of targeted therapies in advanced gastric cancer

(2012) Ferdinando De Vita et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer

(2012) Yung-Jue Bang   JOURNAL OF CLINICAL GASTROENTEROLOGY

HER2 testing in gastric cancer: a practical approach

(2012) Josef Rüschoff et al.   MODERN PATHOLOGY

Update on HER2 testing for breast and upper gastrointestinal tract cancers

(2011) Jeffrey S Ross   Biomarkers in Medicine

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

(2011) Allan Lipton et al.   CANCER

Serum HER2 levels determined by two methods in patients with metastatic breast cancer

(2011) Naoki Hayashi et al.   International Journal of Clinical Oncology

Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls

(2011) Brian Leyland-Jones et al.   LANCET ONCOLOGY

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

(2010) Isabell Witzel et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting

(2009) Patricia Diana Sørensen et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer

(2008) A. Ardavanis et al.   ONCOLOGIST